News

In adults with cystic fibrosis (CF), six of months treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) led to lower levels of biomarkers of inflammation, but higher blood levels of fat-like molecules considered to be cardiovascular risk factors, according to a recent study in Italy. While highly effective, the triple-combination therapy — available…

Oransi has donated air purifiers to help people with cystic fibrosis (CF) affected by smoke-filled air from the wildfires that flared up last month in Southern California, Claire’s Place Foundation said. The foundation’s financial assistance program provides CF patients and their families with one-time funds for air purifiers,…

Clarametyx Biosciences has announced an investment from Kineticos AMR Accelerator (KAMRA) Fund to support the development of CMTX-101, a non-antibiotic treatment candidate for persistent bacterial lung infections in people with cystic fibrosis (CF). This investment, which extends the company’s $33-million financing completed last year, will contribute…

Claire’s Place Foundation, a nonprofit supporting cystic fibrosis (CF) patients and their families, has launched the LA Fire Emergency Fund to help people with CF who are affected by the wildfires that have broken out this month in southern California. This temporary financial assistance program — being…

Prenatal Trikafta treatment of three fetuses with cystic fibrosis (CF) for an intestinal blockage called meconium ileus resulted in different outcomes, potentially due to treatment duration, according to a case series. One infant showed a complete resolution of meconium ileus at birth, one had persistent signs that were…

People with cystic fibrosis (CF) saw sustained reductions in the use of several other CF therapies after two years of treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor), with airway medications and antibiotics being the most reduced, according to a real-world study from Denmark. “This study adds evidence of the real-world impact…

Registration is now open for BreatheCon 2025, an annual online event hosted by the Cystic Fibrosis Foundation that aims to foster connections between adults with cystic fibrosis (CF). This year’s BreatheCon will take place Feb. 7-8. Registration and additional information about the virtual event is available on the…

Claire’s Place Foundation, a nonprofit supporting children and families affected by cystic fibrosis (CF), has launched a CF Ambassador & Advisory program — and is now seeking to grow the new initiative. By involving advocates and people living with CF in the foundation’s mission, and amplifying patient voices…

After one year of treatment with Kaftrio, a triple combination of elexacaftor, tezacaftor, and ivacaftor marketed as Trikafta in the U.S., the number of harmful bacteria growing in the lungs of people with cystic fibrosis (CF) declined significantly, a French study reports. “We observed a significant decrease in…

A Phase 1b trial assessing the safety of RCT2100, Recode Therapeutics’ inhaled therapy candidate for people with cystic fibrosis (CF), has now dosed its first patient in the U.S. The trial already was underway in Europe. RCT2100 is being developed for patients who do not respond to or…